FacebookTwitterGoogle+RedditEmail

Selling One Pill to Treat Side Effects of Another Pill

by MARTHA ROSENBERG

Nearly one in four US women is on antidepressants. The drugs, like Prozac, Paxil and Zoloft, may be happy pills but they are not happy-in-the-bedroom pills. Both older and newer antidepressants cause severe sexual dysfunction like diminished libido and anorgasmia, the inability to achieve orgasm, even with adequate stimulation.

Antidepressant sexual dysfunction is so common, it is used as a sales pitch by the drug manufacturers. “Wellbutrin X works for my depression with a low risk of weight gain and sexual side effects,” say glossy magazine ads showing young men whose sexuality is intact thanks to a better antidepressant. “Can your medicine do all that?” One study found 96 percent patients on a particular antidepressant developed anorgasmia. Who likes those statistics?

Now, marketers of two new sex drugs for women are acknowledging how many women are actually on antidepressants. A Dutch company developing the female libido drugs, Lybrido and Lybridos (which are not yet FDA approved or available) believes the drugs may help the antidepressant-related sexual problems, according to an article in the New York Times magazine. Lybrido contains two possible libido enhancers for women, testosterone and sildenafil, the active ingredient in Viagra. But Lybridos contains testosterone and the antidepressant buspirone, a drug already on the market and known to reverse the negative sexual side effects of antidepressants in some cases by modifying changed levels of the neurotransmitter serotonin that cause the sexual dysfunction.

Buspirone is similar to a “female Viagra” drug that almost reached the market a few years ago. Flibanserin, made by the German company Boehringer Ingelheim, was intended to treat “hypoactive sexual desire disorder” in women but rejected by the FDA. Flibanserin was similar to the antidepressant Serzone which is linked to hyper sexual arousal and the abnormal and painful erectile state known as priapism. Serzone has been withdrawn from markets.

Like Viagra (which had been intended to be an angina drug until its erectile effects appeared) flibanserin, the drug rejected three years ago, was groomed to be an antidepressant drug until its effect on female sexual desire surfaced. Some trial participants did not want to surrender their unused pills at the end of the study. But, despite medical and media excitement about flibanserin and pleas from Big Pharma, Wall Street, husbands, boyfriends and women, the FDA rejected flibanserin in 2010–not for its side effects like dizziness, nausea and sleepiness but because it didn’t seem to work.

Thanks to Big Pharma marketing, Americans increasingly seek a quick fix for “depression,” “sexual dysfunction” and other lifestyle problems. Before direct to consumer marketing of antidepressants, people did not expect to be deliriously happy for no reason or term their problems with marriages and relationships, jobs, health and money, “depression.” Medicalizing lifestyle problems is a cash cow for Big Pharma because advertising works.

Of course, there is no assurance that Lybrido and Lybridos will be approved by the FDA or gain acceptance among doctors and women. But if they do, Big Pharma’s audacious business model of selling one expensive pill to treat side effects of another expensive pill will surely please Wall Street.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

 

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:

CounterPunch Magazine

minimag-edit

bernie-the-sandernistas-cover-344x550

zen economics

December 08, 2016
John W. Whitehead
Power to the People: John Lennon’s Legacy Lives On
Mike Whitney
Rolling Back the Empire: Washington’s Proxy-Army Faces Decisive Defeat in Aleppo
Ellen Brown
“We’ll Look at Everything:” More Thoughts on Trump’s $1 Trillion Infrastructure Plan
John Stauber
The Rise and Fall of Obamacare: Will the Inside Story Ever be Told?
Ted Rall
Ameri-Splaining
Michael J. Sainato
Mainstream Media Continues Absolving Itself From Clinton, Trump Election Failures
Ralph Nader – Mark Green
Divest or Face Impeachment: an Open Letter to Donald Trump
Gareth Porter
US Airstrikes on Syrian Troops: Report Data Undermine Claim of “Mistake”
Martha Burke
What Trumponomics Means for Women
Ramzy Baroud
Fatah, Hold Your Applause: Palestinian Body Politic Rotten to the Core
Steve Horn
Jeff Sessions, Trump’s Attorney General Pick, Introduced First Bill Exempting Fracking from Drinking Water Rules
Joe Ware
The Big Shift: Why Banks Need to Stop Investing Our Money Into Fossil Fuels
Juliana Barnet
On the Ground at Standing Rock
Franklin Lamb
Aleppo Update: An Inspiring Return to the Bombed Out National Museum
Steve Kelly
Hidden Harmony: on the Perfection of Forests
December 07, 2016
Michael Schwalbe
What We Talk About When We Talk About Class
Karl Grossman
The Next Frontier: Trump and Space Weapons
Kenneth Surin
On Being Caught Speeding in Rural America
Chris Floyd
In Like Flynn: Blowback for Filth-Peddling Fascists
Serge Halimi
Trump, the Know-Nothing Victor
Paul DeRienzo
Flynn Flam: Neocon Ex-General to Be Trump’s National Security Advisor
Binoy Kampmark
Troubled Waters: Trump, Taiwan and Beijing
Tom Clifford
Trump and China: a Note From Beijing
Arnold August
Fidel’s Legacy to the World on Theory and Practice
Dave Lindorff
Is Trump’s Idea To Fix a ‘Rigged System’ by Appointing Crooks Who’ve Played It?
John Kirk
Cuba After Fidel
Jess Guh
Repeal of Affordable Care Act is Politics Playing with the Wellbeing of Americans
Eric Sommer
Team Trump: a Government of Generals and Billionaires
Lawrence Davidson
U.S. Reactions to the Death of Fidel Castro
John Garvey - Noel Ignatiev
Abolitionism: a Study Guide
Clancy Sigal
Caution: Conspiracy Theory Ahead!
December 06, 2016
Anthony DiMaggio
Post-Fact Politics: Reviewing the History of Fake News and Propaganda
Richard Moser
Standing Rock: Challenge to the Establishment, School for the Social Movements
Behrooz Ghamari Tabrizi
Warmongering 99 – Common Sense 0: the Senate’s Unanimous Renewal of Iran Sanctions Act
Norman Solomon
Media Complicity is Key to Blacklisting Websites
Michael J. Sainato
Elizabeth Warren’s Shameful Exploitation of Standing Rock Victory
David Rosen
State Power and Terror: From Wounded Knee to Standing Rock
Kim Ives
Deconstructing Another Right-Wing Victory in Haiti
Nile Bowie
South Korea’s Presidency On A Knife-Edge
Mateo Pimentel
Some Notes and a Song for Standing Rock
CJ Hopkins
Manufacturing Normality
Bill Fletcher Jr – Bob Wing
Fighting Back Against the White Revolt of 2016
Peter Lee
Is America Ready for a War on White Privilege?
Pepe Escobar
The Rules of the (Trump) Game
W. T. Whitney
No Peace Yet in Colombia Despite War’s End
FacebookTwitterGoogle+RedditEmail